Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec/Liraglutide vs Xultophy in Chinese T2DM
NCT06559722Phase 3Not yet recruiting
- Sponsor
- Tonghua Dongbao
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of insulin degludec, liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Tonghua Dongbao. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
insulin degludecliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06559722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559722.